TLDR
- Vera Therapeutics shares increased 4% to $35.39 following the release of two-year ORIGIN3 trial results for Trutakna
- The kidney treatment demonstrated efficacy in reducing disease progression to rates comparable with normal aging in IgA nephropathy patients
- The company intends to submit a supplemental Biologics License Application during Q4 for complete FDA authorization
- TD Cowen maintained its Buy recommendation with a $78 target price after reviewing the clinical data
- Despite Tuesday’s gains, VERA shares remain 34% lower in 2026 amid competitive challenges from Vertex and Otsuka
Vera Therapeutics shares advanced 4% to $35.39 on Tuesday following the disclosure of two-year clinical data from the ORIGIN3 study evaluating Trutakna, offering optimism to investors in a stock that has faced headwinds throughout 2026.
The clinical study examined patients diagnosed with immunoglobulin A nephropathy, a kidney disorder characterized by abnormal antibody deposits that impair the organs’ filtration capabilities. The findings demonstrated that Trutakna reduced the rate of kidney function deterioration to levels comparable with natural aging—the gold standard for therapeutic success.
The annualized eGFR slope differential achieved +5.0 mL/min/year compared to placebo. Trutakna produced a two-year annualized eGFR decline of merely -0.6 mL/min/year, aligning with rates typically observed in healthy individuals.
TD Cowen maintained its Buy recommendation and $78 price objective following the data release, describing the kidney function results as among the most impressive outcomes generated in a Phase 3 IgAN clinical trial.
This figure also exceeded the +4.5 mL/min/year placebo-adjusted advantage demonstrated by competing treatment Voyxact, although TD Cowen noted the variance might be within standard measurement variation.
Trial participants additionally exhibited improvements in critical disease indicators, including reduced levels of protein and blood in urine samples. Richard Lafayette, a Stanford nephrology professor and trial investigator, stated the findings offer compelling evidence that Trutakna can diminish long-term risks of dialysis, kidney transplant, or mortality.
Complete FDA Authorization Approaching
Trutakna secured accelerated FDA authorization in July, contingent on its demonstrated capacity to decrease urinary protein levels. To obtain full approval, Vera must now provide confirmatory evidence demonstrating sustained clinical advantages.
The biotechnology firm plans to submit a supplemental Biologics License Application during the fourth quarter. Chief Commercial Officer Matt Skelton reported that within the initial 10 weeks post-launch, Vera received over 350 patient start forms and has begun receiving reimbursement claims.
Wall Street price objectives span from $34 to $100, with the overall consensus rated as Strong Buy. Raymond James upheld a Strong Buy designation with an $84 objective, while Goldman Sachs maintains a Buy rating with an $80 target after a modest reduction. H.C. Wainwright decreased its target to $90 from $125, referencing competitive clinical data from an alternative therapy.
Competition Continues to Weigh
Notwithstanding Tuesday’s advance, VERA shares have declined 34% year-to-date, pressured by an increasingly competitive IgAN treatment landscape.
Otsuka introduced Voyxact in late 2025 via accelerated approval. Although both therapies address the identical condition, Voyxact inhibits a single protein pathway, whereas Trutakna targets two separate proteins.
Vertex is advancing its own dual inhibitor candidate, povetacicept, with a BLA submission accepted for accelerated approval and a regulatory decision date scheduled for November 30. Competitor Vertex stock declined 1% on Tuesday.
The company maintains a cash position exceeding its debt obligations, which TD Cowen and InvestingPro both identified as a significant strength for a clinical-stage biotechnology company.
Get 3 Free Stock Ebooks
Discover top-performing stocks in AI, Crypto, and Technology with expert analysis.
- Top 10 AI Stocks - Leading AI companies
- Top 10 Crypto Stocks - Blockchain leaders
- Top 10 Tech Stocks - Tech giants
